Amit K. Sachdev
Executive Vice President, Chief Patient and External Affairs OfficerVertex Pharmaceuticals
Public PolicyView Profile →Senior Vice President and Chief Access Head · Biogen
Chris Leibman is Biogen’s senior vice president and chief access head, with earlier neuroscience market access leadership at Janssen and Alzheimer immunotherapy work at Élan.
Last reviewed: Nov 2, 2026
Senior Vice President and Chief Access Head
Biogen
Last Reviewed: November 2, 2026
Chris Leibman is Biogen’s senior vice president and chief access head, with earlier neuroscience market access leadership at Janssen and Alzheimer immunotherapy work at Élan.
Leibman trained in biology and pharmacy, then completed a health economics fellowship with GlaxoWellcome and graduate study in pharmacoeconomics and health policy. His work subsequently focused on the evidence and access requirements for pharmaceutical development.
At Élan Pharmaceuticals, and then Janssen AI after its acquisition of the program, he led market access launch-readiness activities for the Alzheimer Immunotherapy Program in partnership with Pfizer. He later became head of market access and policy for neuroscience at Janssen Pharmaceuticals, leading access strategy and value evidence generation across that portfolio.
Leibman joined Biogen in 2014. Before his current global role, he was based in Zug, Switzerland, leading market access and pricing for Europe and Canada. As senior vice president and chief access head, he leads global value evidence, patient access and pricing strategy, alongside public policy and government affairs.
In July 2025, Massachusetts Governor Maura Healey appointed Leibman to the state’s Health Policy Commission. His term runs from July 1, 2025 to June 30, 2028 in the seat requiring expertise in healthcare innovation. He also serves on the Biotechnology Innovation Organization’s executive committee.
Leibman earned a B.S. in biology from the University of Illinois Urbana-Champaign, a Pharm.D. from the University of Illinois Chicago and an M.S. focused on pharmacoeconomics and health policy from Ohio State. He also completed a postdoctoral fellowship in health economics with GlaxoWellcome.